marketcap
Facebook
Twitter
Telegram
Report an ErrorAnnual report 2023
added 11-18-2024
Aeglea BioTherapeutics Income Statement 2011-2024 | AGLE
Annual Income Statement Aeglea BioTherapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
82.8 M | 1.35 M | 12.5 M | 420 M | 226 M | 187 M | 104 M | 39.3 M | - | - | - | - | - |
Shares |
6.9 M | 3.37 M | 2.63 M | 53.4 M | 31.9 M | 20.8 M | 15.1 M | 9.79 M | - | - | - | - | - |
Historical Prices |
12 | 0.4 | 4.75 | 7.87 | 7.64 | 7.49 | 5.41 | 4.35 | - | - | - | - | - |
Net Income |
-339 M | -83.8 M | -65.8 M | -80.9 M | -78.3 M | -44.3 M | -27.2 M | -21.7 M | -11.3 M | -10.3 M | - | - | - |
Revenue |
886 K | 2.33 M | 18.7 M | 21.8 K | - | 3.89 M | 5.2 M | 4.63 M | 6.08 M | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-242 M | -84.8 M | -65.6 M | -81.5 M | -80.3 M | -45.5 M | -27.7 M | -21.9 M | -11.3 M | -8.9 M | - | - | - |
Interest Expense |
-19.1 M | -7 K | -122 K | -5 K | -63 K | -57 K | -42 K | -36 K | -2 K | - | - | - | - |
EBITDA |
-242 M | -83.2 M | -64.1 M | -80.5 M | -79.9 M | -45.2 M | -27.4 M | -21.8 M | -11.2 M | -7.44 M | - | - | - |
Operating Expenses |
243 M | 87.1 M | 84.4 M | 81.5 M | 80.3 M | 49.4 M | 32.9 M | 26.5 M | 17.4 M | - | - | - | - |
General and Administrative Expenses |
39.9 M | 28.5 M | 27.3 M | 21.8 M | 15.7 M | 12.6 M | 10.1 M | 8.39 M | 5.95 M | 2.07 M | - | - | - |
All numbers in USD currency
Quarterly Income Statement Aeglea BioTherapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
50.9 M | 45.3 M | 36.5 M | 36.1 M | 4.29 M | 3.82 M | 3.77 M | 2.61 M | 3.77 M | 82.2 M | 66 M | 49.4 M | 65.8 M | 65.6 M | 65.6 M | 48 M | 62.2 M | 52.9 M | 33.1 M | 29.1 M | 32.9 M | 32.8 M | 29 M | 24.1 M | 22 M | 20.6 M | 16.7 M | 16.7 M | 16.4 M | 14.1 M | 13.4 M | 13.4 M | 13.3 M | 11.8 M | 641 K | 757 K | 613 K | 586 K | 573 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-69 M | -38.8 M | -43.9 M | - | -40.1 M | -217 M | -18.4 M | - | -18.2 M | -22.3 M | -24.4 M | - | -20.3 M | -6.83 M | -18.2 M | -22.7 M | -18 M | -21.4 M | -18.7 M | -21.5 M | -21.6 M | -18 M | -17.2 M | -14.9 M | -11.9 M | -9.41 M | -8.12 M | -6.48 M | -7.87 M | -6.63 M | -6.25 M | -5.48 M | -6.24 M | -5.43 M | -4.55 M | -3.99 M | -3.41 M | -1.43 M | -2.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | - | - | - | - | 688 K | 198 K | - | 174 K | 625 K | 1.36 M | - | 1.4 M | 13.7 M | - | - | - | - | - | - | - | - | - | - | - | 2.38 M | 1.51 M | 1.48 M | 1.26 M | 1.48 M | 982 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-55.4 M | -44.1 M | -47.8 M | - | -18.3 M | -159 M | -18.8 M | - | -18.8 M | -22.4 M | -24.4 M | - | -20.3 M | -6.7 M | -18.2 M | -22.8 M | -18.1 M | -21.6 M | -19 M | -21.9 M | -22.1 M | -18.6 M | -17.7 M | -15.3 M | -12.2 M | -9.67 M | -8.24 M | -6.63 M | -8 M | -6.72 M | -6.33 M | -5.54 M | -6.3 M | -5.5 M | -4.57 M | -4 M | -3.42 M | -1.43 M | -2.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-18.8 M | -610 K | -483 K | - | 2.34 M | -8 K | -72 K | - | 24 K | 5 K | -30 K | - | -24 K | -52 K | -31 K | - | 2 K | -19 K | -6 K | - | -12 K | -16 K | -17 K | - | -13 K | -7 K | -17 K | - | -12 K | -12 K | -11 K | - | -9 K | -9 K | -6 K | - | -1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
- | - | - | - | - | - | -18.4 M | - | -17.6 M | -22.4 M | -24 M | - | -19.1 M | -6.7 M | -17.9 M | -22.8 M | -17.5 M | -21.2 M | -18.9 M | -21.9 M | -21.8 M | -18.4 M | -17.6 M | -15.3 M | -12 M | -9.52 M | -8.18 M | -6.63 M | -7.82 M | -6.61 M | -6.28 M | -5.54 M | -6.2 M | -5.43 M | -4.54 M | -4 M | -3.36 M | -1.4 M | -2.45 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
55.4 M | 44.1 M | 47.8 M | - | 18.3 M | 160 M | 19 M | - | 18.9 M | 23 M | 25.8 M | - | 21.7 M | 20.4 M | 18.2 M | - | 18.1 M | 21.6 M | 19 M | - | 22.1 M | 18.6 M | 17.7 M | - | 12.2 M | 12 M | 9.76 M | - | 9.26 M | 8.2 M | 7.31 M | - | 7.45 M | 6.87 M | 5.43 M | - | 4.49 M | 4.86 M | 2.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
10.6 M | 11.5 M | 12.8 M | - | 8.58 M | 12.1 M | 5.23 M | - | 6.95 M | 7.68 M | 8.82 M | - | 6.84 M | 6.82 M | 6.35 M | - | 5.67 M | 4.69 M | 4.46 M | - | 4.31 M | 3.82 M | 3.27 M | - | 3.31 M | 2.93 M | 2.88 M | - | 3.02 M | 2.36 M | 2.36 M | - | 2.06 M | 2.45 M | 1.83 M | - | 1.36 M | 2.12 M | 847 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency